Messages in brief
Creating Accessible Package Leaflets
messages in brief
|
27/07/2020
We have published updated versions for human accessible Package Leaflets and the QRD template!
Creating Accessible Package Leaflets
Read more
BREXIT Transition period
messages in brief
|
09/07/2020
The EC has published a useful summary of applicable EU rules after the end of the transition period. You can find the link here on the website of the BASG.
BREXIT Transition period
Read more
Creating Accessible Package Leaflets
messages in brief
|
01/07/2020
In an arbitration process, the Federal Office for Safety in Health Care (BASG) was obliged according to § 14 of the Federal Disability Equality Act (BGStG) to request Holders of a Marketing authorization/Registration/Parallel import license to provide their Package Leaflets (PL) in an accessible format corresponding to the standard PDF-UA until 31.12.2020.
Creating Accessible Package Leaflets
Read more
Save the Date: BASG-dialogue “Meet the Case Manager”
messages in brief
|
30/06/2020
In 2017, we have received a lot of positive feedback for our first BASG-dialogue “Meet the Case Manager”. Therefore, we are very happy to announce your next chance to meet with us in person!
Save the Date: BASG-dialogue “Meet the Case Manager”
Read more
The „RMS NEWS“ are back!
messages in brief
|
30/06/2020
Also in the future, we want to continue to inform our applicants of marketing authorisation procedures with Austria as RMS with relevant news from the committees or exciting innovations such as the slot application via our eServices!
The „RMS NEWS“ are back!
Read more
Erste COVID-19-Behandlung für EU-Zulassung empfohlen
messages in brief
|
25/06/2020
Bedingte Zulassung für Wirkstoff Remdesivir, für Erwachsene und Jugendliche ab 12 Jahren mit COVID-19 Lungenentzündung die Sauerstoff benötigen, empfohlen
Erste COVID-19-Behandlung für EU-Zulassung empfohlen
Read more
COVID-19: Warnung vor dubiosen Produkten die als „wirksam gegen COVID-19“ angeboten werden
messages in brief
|
24/06/2020
Die Warnung umfasst Produkte die außerhalb von legalen Apotheken angeboten werden
COVID-19: Warnung vor dubiosen Produkten die als „wirksam gegen COVID-19“ angeboten werden
Read more
COVID-19: Erinnerung an Risiken von Chloroquin und Hydroxychloroquin
messages in brief
|
29/05/2020
Vorteilhafte Wirkung nicht belegt, aber Hinweise auf gravierende Nebenwirkungen
COVID-19: Erinnerung an Risiken von Chloroquin und Hydroxychloroquin
Read more
Warnung vor unkontrollierten zell-basierten Therapien mit mangelnder Evidenz
messages in brief
|
30/04/2020
Only available in German
Warnung vor unkontrollierten zell-basierten Therapien mit mangelnder Evidenz
Read more
COVID-19: Nebenwirkungsmeldungen
messages in brief
|
30/04/2020
Only available in German
COVID-19: Nebenwirkungsmeldungen
Read more